title: Nestin expression in high-grade osteosarcomas and its clinical significance.
abstract: Nestin has been detected in various malignancies and its expression correlates             with advanced grade in some neoplasms. The aim of this study was to examine nestin             expression in high-grade osteosarcomas and to determine its prognostic value.             Using immunohistochemistry and immunofluorescence, we evaluated nestin expression             in tumor tissue samples from 45 patients with high-grade osteosarcomas. In both             methods, the frequency of nestin-positive tumor cells was classified into three             categories (1+, 2+ and 3+ for immunohistochemistry; 1F+, 2F+ and 3F+ for immunofluorescence)             and clinicopathological correlations were statistically evaluated and analyzed.             Nestin-positive tumor cells were detected in all of the examined osteosarcomas             using both immunohistochemistry and immunofluorescence, although the proportion             of undoubtedly positive neoplastic cells varied in individual samples from a few             nestin-positive tumor cells to diffuse nestin positivity. High levels of nestin             expression detected by immunofluorescence (2F+ and 3F+) were associated with worse             clinical outcomes (OS, p=0.031; EFS, p<0.001). However, high levels of nestin             expression as measured by immunohistochemistry trended towards shorter patient             survival rates but did not reach statistical significance. Despite significantly             shorter survival rates observed in patients with high levels of nestin expression             assessed by immunofluorescence, nestin does not seem to represent a powerful prognostic             marker that would be superior to conventional methods.
authors.affiliation: First Department of Pathological Anatomy, Medical Faculty of                     Masaryk University and St. Anne's University Hospital, 65691 Brno, Czech                     Republic.
authors.forename: Iva
authors.initials: I
authors.lastname: Zambo
authors.forename: Marketa
authors.initials: M
authors.lastname: Hermanova
authors.forename: Dagmar
authors.initials: D
authors.lastname: Adamkova Krakorova
authors.forename: Peter
authors.initials: P
authors.lastname: Mudry
authors.forename: Karel
authors.initials: K
authors.lastname: Zitterbart
authors.forename: Michal
authors.initials: M
authors.lastname: Kyr
authors.forename: Karel
authors.initials: K
authors.lastname: Vesely
authors.forename: Jaroslav
authors.initials: J
authors.lastname: Sterba
authors.forename: Renata
authors.initials: R
authors.lastname: Veselska
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001859:Bone Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000473:pathology*; D002648:Child; D005260:Female; D006801:Humans; D007381:Intermediate Filament Proteins / Q000235:genetics / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D009419:Nerve Tissue Proteins / Q000235:genetics / Q000378:metabolism*; D064231:Nestin; D012516:Osteosarcoma / Q000378:metabolism* / Q000401:mortality / Q000473:pathology*; D011379:Prognosis; D055815:Young Adult
chemical_list: D007381:Intermediate Filament Proteins; C577484:NES protein, human; D009419:Nerve Tissue Proteins; D064231:Nestin